The Wolverine stack is a popular nickname for injecting two unapproved peptides, BPC-157 and TB-500, together to speed recovery from injuries.[1] Each has shown healing effects in animals, but the combination has never been tested in a human trial, and the one animal study of the pair found no extra benefit from using both.[12] Neither peptide is FDA-approved.[11]
This guide covers where the name comes from, what each peptide is, the evidence, the reasons people combine them, side effects, contamination risks and the 2026 legal picture.
Where the “Wolverine” name comes from
The name is a nod to Wolverine, the Marvel character known for healing almost instantly.[2] It is a marketing and internet label, not a medical term, and we found no reliable record of who coined it. Reuters reported in September 2026 that BPC-157 is often taken with TB-500 “in a combination popularly known as the Wolverine stack.”[1]
There is no fixed recipe. Sellers vary the amounts, and some add other peptides. For blends that add more ingredients, see our GLOW and KLOW guides.
What are BPC-157 and TB-500?
BPC-157 is a lab-made chain of 15 amino acids based on a fragment of a stomach protein. Despite more than 30 years of animal research, it has no approved formulation and no validated dose.[4] In rat and cell studies, it increased blood vessel growth, linked to VEGFR2 and nitric oxide (eNOS) signaling.[31]
TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, a natural protein that helps cells move. The fragment (Ac-LKKTETQ) is the part that binds actin, a building block of the cell’s skeleton.[9][15] TB-500 is not the same as full-length thymosin beta-4, and results for one do not automatically apply to the other.
BPC-157 vs TB-500 at a glance
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | 15-amino-acid peptide from a stomach protein[4] | 7-amino-acid fragment of thymosin beta-4[9] |
| Proposed action | Blood vessel growth and nitric oxide signaling[31] | Actin binding, cell movement[10] |
| Half-life | Under 30 minutes in rats and dogs[32] | Cleared within 6 to 10 hours in horses[11] |
| Human studies | A few small studies; the three published pilots had no control group[4][11] | None[11] |
| FDA-approved? | No[11] | No[11] |
| WADA | Prohibited (S0, non-approved substances)[25] | Prohibited (S2, growth factors)[25] |
What the research shows for each peptide
BPC-157
A 2025 systematic review found 36 studies of BPC-157 for muscle, tendon, ligament and bone; 35 were preclinical (animal or lab) studies and 1 was in people.[3] In rats with a cut Achilles tendon, it improved tendon strength and structure.[8]
Human evidence is thin. A 2026 review counted fewer than 30 people across three small published studies, none with a comparison group.[4] FDA’s 2026 review also lists earlier enema studies in healthy volunteers and people with ulcerative colitis.[11] The three published pilots:
- Knee pain: 14 of 16 patients at a Florida clinic reported relief after knee injections, measured by phone survey.[5]
- Bladder pain: 10 of 12 women with interstitial cystitis reported complete relief after a single injection.[6]
- IV safety: 2 adults showed no measurable changes in safety blood tests.[7]
TB-500
In aged mice, a synthetic seven-amino-acid peptide with the same sequence as TB-500 (without its acetyl cap) sped skin wound repair about as well as the full protein.[10] A 2024 Korean study suggested that a breakdown product, not TB-500 itself, may account for wound-healing activity in cells.[15]
FDA found no studies in which TB-500 was given to people.[11] Human trials exist only for full-length thymosin beta-4, a different molecule: as eye drops for dry eye[13] and as IV doses that were well tolerated in healthy volunteers.[14]
Why people combine them
The claimed rationale is that the two peptides work in different ways: BPC-157 through blood vessel growth, TB-500 through cell movement and actin. Promoters argue that hitting both pathways should heal tissue faster than either alone. That idea is a hypothesis; it has not been shown in people.
Has the Wolverine stack been studied?
No clinical trial has tested BPC-157 and TB-500 together. Two pieces of research come closest:
- Rats (Türkiye, 2026): 32 rats with repaired Achilles tendons got BPC-157, TB-500, both, or nothing for four weeks. TB-500 alone significantly increased tendon strength. Combining the two gave no additional benefit over either alone.[12]
- People (Florida, 2021): in the knee-pain chart review, 12 patients received BPC-157 alone and 4 received injections of BPC-157 plus thymosin beta-4. Three of those 4 reported significant improvement. The study did not say the product was TB-500 specifically, had no control group, and used a phone survey rather than validated scoring.[5]
Wolverine stack dosage: what has been studied
No dose of the combination has been studied in people. In the rat study, the animals received 10 mcg per kg of BPC-157 and 60 mcg per kg of TB-500 per day, injected into the abdomen.[12] Animal doses do not translate directly to humans. The amounts sellers list come from marketing, not trials.
If you are working out what is in a vial, our guide on how to reconstitute peptides and the peptide calculator explain the math. This is not a recommendation to use either peptide.
Side effects and contamination risks
- Unknown human safety: BPC-157’s three small studies reported no serious side effects but monitored little; TB-500 has no human safety data and no animal toxicity studies.[4][11]
- A report linked to the pair: FDA described a report of skin and gum darkening that came back when a person used BPC-157 with TB-500 again; the cause was unclear.[11]
- Reported harms: in a 2026 analysis of more than 15 million medical records by the data firm nference, some patients who stopped BPC-157 cited neuropsychiatric, skin and gut symptoms, according to Reuters. The analysis was not peer reviewed; Reuters said the report was published ahead of peer review.[1] KFF Health News described people reporting fatigue, anxiety or severe migraine after using peptides from online sellers.[19]
- Theoretical cancer concern: BPC-157 promotes blood vessel growth, and beta-thymosins are involved in tumor cell spread, so doctors raise a theoretical risk of helping existing cancers grow. No study has shown this in people.[18][28]
- Contamination and mislabeling: a French lab found that the contents of online “TB500” and “TB1000” products did not consistently match their descriptions.[16] FDA’s main concern for these peptides is immune reactions from impurities or clumped peptide.[20] A 2026 review warns that unregulated injectable peptides carry risks from contamination and dosing errors.[17]
What users report
Is the Wolverine stack legal? FDA and WADA status in 2026
- Not FDA-approved. Neither peptide is part of any approved drug.[11]
- Compounding history: FDA listed both among substances that may pose significant safety risks in compounding, then removed them in April 2026 after the nominations were withdrawn, which is not an approval.[20][21]
- July 2026 vote: FDA reviewed BPC-157 and TB-500 and recommended against both, but its Pharmacy Compounding Advisory Committee reportedly voted 8 to 6, with one abstention, in favor of each.[22][24][23] The vote is not binding, and no rule had followed as of our last review.
- Banned in sport: WADA’s 2026 list names BPC-157 under S0 (non-approved substances) and thymosin beta-4 derivatives such as TB-500 under S2 (growth factors), and lists both classes as prohibited at all times, in and out of competition.[25] USADA also warns athletes that BPC-157 is prohibited.[26]
This is general information, not legal or medical advice. For other compounds in this group, see our healing peptides category and the healing peptides hub.
